Lars Jakobsen

Lars Jakobsen

Auto-generated profile, based on publicly available information

Lars Jakobsen

Department of Cardiology Aarhus University Hospital Aarhus Denmark

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
LJLars Jakobsen
Lars Jakobsen
TNTroels Niemann
Troels Niemann
NTNiels Thorsgaard
Niels Thorsgaard
LTLeif Thuesen
Leif Thuesen
JLJens F. Lassen
Jens F. Lassen
SJSøren P. Johnsen
Søren P. Johnsen
Background—: The association between low socioeconomic status (SES) and high mortality from coronary heart disease is well-known. However, the role of SES in relation to the clinical outcome after primary percutaneous coronary intervention remains poorly understood. Methods and Results—: We studied 7385 patients treated with primary percutaneous coronary intervention. Participants were divided into high-SES and low-SES groups according to income, education, and employment status. The primary outcome was major adverse cardiac events (cardiac death, recurrent myocardial infarction, and target vessel revascularization) at maximum follow-up (mean, 3.7 years). Low-SES patients had more adverse baseline risk profiles than high-SES patients. The cumulative risk of major adverse cardiac events after maximum follow-up was higher among low-income patients and unemployed patients compared with their counterparts (income: hazard ratio, 1.68; 95% CI, 1.47–1.92; employment status: hazard ratio, 1.75; 95% CI, 1.46–2.10). After adjustment for patient characteristics, these differences were substantially attenuated (income: hazard ratio, 1.12; 95% CI, 0.93–1.33; employment status: hazard ratio, 1.27; 95% CI, 1.03–1.56). Further adjustment for admission findings, procedure-related data, and medical treatment during follow-up did not significantly affect the associations. With education as the SES indicator, no between-group differences were observed in the risk of the composite end point. Conclusions—: Even in a tax-financed healthcare system, low-SES patients treated with primary percutaneous coronary intervention face a worse prognosis than high-SES patients. The poor outcome seems to be largely explained by differences in baseline patient characteristics. Employment status and income (but not education level) were associated with clinical outcomes.

1 June 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
LJLars Jakobsen
Lars Jakobsen
ECEvald H. Christiansen
Evald H. Christiansen
PFPhillip Freeman
Phillip Freeman
JKJohnny Kahlert
Johnny Kahlert
KVKarsten Veien
Karsten Veien
LJLisette O. Jensen
Lisette O. Jensen
Background: Target lesion failure remains an issue with contemporary drug-eluting stents. Thus, the dual-therapy sirolimus-eluting and CD34+ antibody–coated Combo stent (DTS) was designed to further improve early healing. This study aimed to investigate whether the DTS is noninferior to the sirolimus-eluting Orsiro stent (SES) in an all-comers patient population. Methods: The SORT OUT X (Combo Stent Versus Orsiro Stent) trial, was a large-scale, randomized, multicenter, single-blind, 2-arm, noninferiority trial with registry-based follow-up. The primary end point target lesion failure was a composite of cardiac death, myocardial infarction, or target lesion revascularization within 12 months, analyzed using intention-to-treat. The trial was powered for assessing target lesion failure noninferiority of the DTS compared with the SES with a predetermined noninferiority margin of 0.021. Results: A total of 3146 patients were randomized to treatment with the DTS (1578 patients; 2008 lesions) or SES (1568 patients; 1982 lesions). At 12 months, intention-to-treat analysis showed that 100 patients (6.3%) assigned the DTS and 58 patients (3.7%) assigned the SES met the primary end point (absolute risk difference, 2.6% [upper limit of 1-sided 95% CI, 4.1%]; P (noninferiority)=0.76). The SES was superior to the DTS (incidence rate ratios for target lesion failure, 1.74 [95% CI, 1.26–2.41]; P =0.00086). The difference was explained mainly by a higher incidence of target lesion revascularization in the DTS group compared with the SES group (53 [3.4%] vs. 24 [1.5%]; incidence rate ratio, 2.22 [95% CI, 1.37–3.61]; P =0.0012). Conclusions: The DTS did not confirm noninferiority to the SES for target lesion failure at 12 months in an all-comer population. The SES was superior to the DTS mainly because the DTS was associated with an increased risk of target lesion revascularization. However, rates of death, cardiac death, and myocardial infarction at 12 months did not differ significantly between the 2 stent groups. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03216733.

21 November 2022 in American Heart Journal
Verified
Journal Article
Open access
TRTruls Råmunddal
Truls Råmunddal
EHEmil Nielsen Holck
Emil Nielsen Holck
SKSalma Karim
Salma Karim
AEAshkan Eftekhari
Ashkan Eftekhari
JEJavier Escaned
Javier Escaned
ECEvald Høj Christiansen
Evald Høj Christiansen
Chronic total occlusions (CTO) are frequent among patients with coronary artery disease. Revascularization with percutaneous coronary intervention (PCI) is safe and feasible in experienced hands. However, randomized data are needed to demonstrate symptomatic as well as prognostic effect of CTO-PCI compared to optimal medical therapy alone. This trial aims to evaluate the effect of CTO PCI in patients with a CTO lesion and target vessel diameter ≥ 2.5 mm, and myocardial ischemia in the relevant territory. First, all patients are subjected to optimal medical therapy (OMT) for at least for 3 months and non-CTO lesions are managed according to guidelines. Subsequently, prior to randomization myocardial ischemia and quality of life (Seattle Questionnaire (SAQ)) is assessed. Patients are divided into two cohorts based on their SAQ score and randomized to either OMT alone or OMT and CTO-PCI. Cohort A is defined as Low- or asymptomatic patients with a quality-of-life score > 60 and/or CCS class < 2, and more than 10 % ischemia in the left ventricle (LV). Cohort B is symptomatic patients with a quality-of-life score < 60 or CCS class angina > 1 and at least ischemia in 5% of the LV. The primary end-point in cohort A is a composite of major adverse cardiac and cerebral events, hospitalization for heart failure and malignant ventricular arrhythmias. The primary endpoint in cohort B is difference in quality of life 6 months after randomization. This trial is designed to investigate if CTO-PCI improves QoL and MACCE. Both positive and negative outcome of the trial will affect future guidelines and recommendations on how to treat patients with CTO.

1 December 2012 in EuroIntervention
Verified
Journal Article
Closed access
LJLars Jakobsen
Lars Jakobsen
TNTroels Niemann
Troels Niemann
NTNiels Thorsgaard
Niels Thorsgaard
TNTorsten T. Nielsen
Torsten T. Nielsen
LTLeif Thuesen
Leif Thuesen
SJSøren P. Johnsen
Søren P. Johnsen
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

1 August 2023 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
SHSigne Højstrup
Signe Højstrup
KHKim W. Hansen
Kim W. Hansen
UTUlrik Talleruphuus
Ulrik Talleruphuus
LMLisbeth Marner
Lisbeth Marner
LBLouise Bjerking
Louise Bjerking
EPEva Prescott
Eva Prescott
BACKGROUND: Rubidium-82 positron emission tomography ( 82 Rb PET) myocardial perfusion imaging is used in clinical practice to quantify regional perfusion defects. Additionally, 82 Rb PET provides a measure of absolute myocardial flow reserve (MFR), describing the vasculature state of health. We assessed whether 82 Rb PET-derived MFR is associated with all-cause mortality independently of the extent of perfusion defects. METHODS: We conducted a multicenter clinical registry-based study of patients undergoing 82 Rb PET myocardial perfusion imaging on suspicion of chronic coronary syndromes. Patients were followed up in national registries for the primary outcome of all-cause mortality. Global MFR ≤2 was considered reduced. RESULTS: Among 7169 patients studied, 38.1% were women, the median age was 69 (IQR, 61–76) years, and 39.0% had MFR ≤2. A total of 667 (9.3%) patients died during a median follow-up of 3.1 (IQR, 2.6–4.0) years, more in patients with MFR ≤2 versus MFR >2 (15.7% versus 5.2%; P <0.001). MFR ≤2 was associated with all-cause mortality across subgroups defined by the extent of perfusion defects (all P <0.05). In a Cox survival regression model adjusting for sex, age, comorbidities, kidney function, left ventricular ejection fraction, and perfusion defects, MFR ≤2 was a robust predictor of mortality with a hazard ratio of 1.62 (95% CI, 1.31–2.02; P <0.001). Among patients with no reversible perfusion defects (n=3101), MFR ≤2 remained strongly associated with mortality (hazard ratio, 1.86 [95% CI, 1.26–2.73]; P <0.01). The prognostic value of impaired MFR was similar for cardiac and noncardiac death. CONCLUSIONS: MFR ≤2 predicts all-cause mortality independently of the extent of perfusion defects. Our results support the inclusion of MFR when assessing the prognosis of patients suspected of chronic coronary syndromes.

1 April 2018 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
TCTor Skibsted Clemmensen
Tor Skibsted Clemmensen
NHNiels Ramsing Holm
Niels Ramsing Holm
HEHans Eiskjær
Hans Eiskjær
LJLars Jakobsen
Lars Jakobsen
KBKatrine Berg
Katrine Berg
SPSteen Hvitfeldt Poulsen
Steen Hvitfeldt Poulsen